TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy As Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients With RRMS
Brief Summary: This is a phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex (interferon beta-1a) controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS).


Options:
A: Arm Label: Initial IFNB-1b (Interferon beta-1b); Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Arm Label: Initial Placebo; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Intervention Type: DRUG; Name: Interferon beta-1b (Betaseron, BAY86-5046); Assigned to Arm(s): Initial IFNB-1b (Interferon beta-1b) | Intervention Type: DRUG; Name: Interferon beta-1b (Betaseron, BAY86-5046); Assigned to Arm(s): Initial Placebo
B: Arm Label: RNF 44 mcg thrice weekly; Type: ACTIVE_COMPARATOR; Interventions: Drug: RNF | Arm Label: RNF 44 mcg once weekly and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: RNF, Drug: Placebo | Arm Label: Placebo/RNF 44 mcg thrice weekly; Type: ACTIVE_COMPARATOR; Interventions: Drug: RNF | Intervention Type: DRUG; Name: RNF; Assigned to Arm(s): RNF 44 mcg thrice weekly | Intervention Type: DRUG; Name: RNF; Assigned to Arm(s): RNF 44 mcg once weekly and placebo | Intervention Type: DRUG; Name: RNF; Assigned to Arm(s): Placebo/RNF 44 mcg thrice weekly | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): RNF 44 mcg once weekly and placebo
C: Arm Label: Immediate Treatment Group; Type: EXPERIMENTAL; Interventions: Drug: interferon beta 1a 30 ug IM once weekly | Arm Label: Delayed Treatment Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: interferon beta 1a 30 ug IM once weekly | Intervention Type: DRUG; Name: interferon beta 1a 30 ug IM once weekly; Assigned to Arm(s): Delayed Treatment Group, Immediate Treatment Group
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Ocrelizumab 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Ocrelizumab 1000 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Avonex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Avonex | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab 1000 mg, Ocrelizumab 600 mg | Intervention Type: DRUG; Name: Avonex; Assigned to Arm(s): Avonex

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy As Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients With RRMS
Brief Summary: This is a phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex (interferon beta-1a) controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Ocrelizumab 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Ocrelizumab 1000 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Avonex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Avonex | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab 1000 mg, Ocrelizumab 600 mg | Intervention Type: DRUG; Name: Avonex; Assigned to Arm(s): Avonex
B: Arm Label: Rebif®; Type: EXPERIMENTAL; Interventions: Drug: Rebif® | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone® | Intervention Type: DRUG; Name: Rebif®; Assigned to Arm(s): Rebif® | Intervention Type: DRUG; Name: Copaxone®; Assigned to Arm(s): Copaxone®
C: Arm Label: Atacicept 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Atacicept 75 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Atacicept 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matched to atacicept | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 25 mg | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 75 mg | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 150 mg | Intervention Type: DRUG; Name: Placebo matched to atacicept; Assigned to Arm(s): Placebo
D: Arm Label: OMB 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab subcutaneous injection, Drug: Teriflunomide-matching placebo capsules | Arm Label: TER 14 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Teriflunomide capsule, Drug: Matching placebo of ofatumumab subcutaneous injections | Intervention Type: DRUG; Name: Ofatumumab subcutaneous injection; Assigned to Arm(s): OMB 20 mg | Intervention Type: DRUG; Name: Teriflunomide-matching placebo capsules; Assigned to Arm(s): OMB 20 mg | Intervention Type: DRUG; Name: Teriflunomide capsule; Assigned to Arm(s): TER 14 mg | Intervention Type: DRUG; Name: Matching placebo of ofatumumab subcutaneous injections; Assigned to Arm(s): TER 14 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Trial of Oral L-arginine and / or Vitamin D as Adjunctive Therapies in Pulmonary Tuberculosis in Papua Province, Indonesia.
Brief Summary: The purpose of this study is to determine whether adjunctive L-arginine and vitamin D can improve response to standard short course TB therapy in people with newly diagnosed pulmonary TB.


Options:
A: Arm Label: Study drug containing zinc alone; Type: EXPERIMENTAL; Interventions: Drug: Zinc | Arm Label: Study drug Micronutrient without zinc; Type: EXPERIMENTAL; Interventions: Drug: Micronutrient without zinc | Arm Label: Study drug Micronutrient with zinc; Type: EXPERIMENTAL; Interventions: Drug: Micronutrient with zinc | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): Study drug containing zinc alone | Intervention Type: DRUG; Name: Micronutrient without zinc; Assigned to Arm(s): Study drug Micronutrient without zinc | Intervention Type: DRUG; Name: Micronutrient with zinc; Assigned to Arm(s): Study drug Micronutrient with zinc | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: BEHAVIORAL; Name: food; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: L-arginine, Drug: Vitamin D | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D, Drug: Placebo L-arginine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: L-arginine, Drug: Placebo Vitamin D | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo L-arginine, Drug: Placebo Vitamin D | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo L-arginine; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: Placebo Vitamin D; Assigned to Arm(s): 3, 4
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Multivitamins; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamin supplement containing vitamins B, C, and E | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin supplement containing vitamins B, C, and E; Assigned to Arm(s): Multivitamins | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Efficacy of Three Dosage Regimens of MP-376 Solution for Inhalation Given for 28 Days to Stable CF Patients
Brief Summary: Patients with cystic fibrosis (CF) suffer from chronic infections of the lower respiratory tract that can be caused by one or multiple bacteria, including Pseudomonas aeruginosa, which has been particularly problematic to eradicate and been implicated as the major cause of morbidity and mortality in CF patients. Aerosol delivery of antibiotics directly to the lung increases the local concentrations of antibiotic at the site of infection resulting in improved antimicrobial effects compared to systemic administration. Bacterial resistance to current aerosol antibiotic treatments indicate a need for improved therapies to treat CF patients with pulmonary infections caused by multi-drug resistant Pseudomonas aeruginosa and other bacteria. High concentrations of MP-376 delivered directly to the lung are projected to have antimicrobial effects on even the most resistant organisms.


Options:
A: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
B: Arm Label: Observational; Type: N/A; Interventions: N/A
C: Arm Label: AZLI; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZLI, Drug: Tobramycin inhalation solution | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match AZLI, Drug: Tobramycin inhalation solution | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI | Intervention Type: DRUG; Name: Placebo to match AZLI; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tobramycin inhalation solution; Assigned to Arm(s): AZLI, Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MP-376 120 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg BID; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Intervention Type: DRUG; Name: MP-376; Assigned to Arm(s): MP-376 120 mg QD, MP-376 240 mg BID, MP-376 240 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Cardiovascular Risk With Dietary Flavonoids in Post Menopausal Women With Type 2 Diabetes
Brief Summary: The purpose of this placebo controlled trial is to determine whether a year long intervention with flavonoids (found in cocoa and soy) is more effective in reducing the risk of cardiovascular disease in postmenopausal women with type 2 diabetes, than standard therapy (statins). A range of markers of cardiovascular disease risk are being studied and volunteers are also providing urine and blood samples. 152 postmenopausal women, from the locality, will be recruited for this study.


Options:
A: Arm Label: Intervention A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Flavonoid enrichment (cocoa / soy compounds) | Arm Label: Intervention B; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Flavonoid enrichment (cocoa / soy compounds) | Intervention Type: DIETARY_SUPPLEMENT; Name: Flavonoid enrichment (cocoa / soy compounds); Assigned to Arm(s): Intervention A | Intervention Type: DIETARY_SUPPLEMENT; Name: Flavonoid enrichment (cocoa / soy compounds); Assigned to Arm(s): Intervention B
B: Arm Label: Low- polyphenol diet; Type: OTHER; Interventions: Other: Two portions of fruit and vegetables per day (excluding berries and dark chocolate) | Arm Label: High-polyphenol diet; Type: ACTIVE_COMPARATOR; Interventions: Other: Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate. | Intervention Type: OTHER; Name: Two portions of fruit and vegetables per day (excluding berries and dark chocolate); Assigned to Arm(s): Low- polyphenol diet | Intervention Type: OTHER; Name: Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.; Assigned to Arm(s): High-polyphenol diet
C: Intervention Type: DRUG; Name: dark chocolate; Assigned to Arm(s): N/A
D: Arm Label: Theobromine drink; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Theobromine | Arm Label: Cocoa drink; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cocoa | Arm Label: Placebo drink; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Cocoa and theobromine drink; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cocoa and theobromine | Intervention Type: DIETARY_SUPPLEMENT; Name: Theobromine; Assigned to Arm(s): Theobromine drink | Intervention Type: DIETARY_SUPPLEMENT; Name: Cocoa; Assigned to Arm(s): Cocoa drink | Intervention Type: DIETARY_SUPPLEMENT; Name: Cocoa and theobromine; Assigned to Arm(s): Cocoa and theobromine drink | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo drink

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Text Message Reminders on Contraceptive Continuation, a Randomized Controlled Trial
Brief Summary: Teen girls and young women taking birth control pills may forget to take their pills or may stop taking them altogether. This places them at risk for unintended pregnancies. Most young women own cell phones and use them for text messaging. We will test whether contraceptive continuation is affected after six months of daily text message reminders.


Options:
A: Arm Label: Positive adjustment coping intervention; Type: EXPERIMENTAL; Interventions: Other: Positive adjustment coping intervention | Arm Label: Brainteaser; Type: OTHER; Interventions: Other: Brainteaser | Intervention Type: OTHER; Name: Positive adjustment coping intervention; Assigned to Arm(s): Positive adjustment coping intervention | Intervention Type: OTHER; Name: Brainteaser; Assigned to Arm(s): Brainteaser
B: Arm Label: Connected to Care; Type: EXPERIMENTAL; Interventions: Behavioral: Connected to Care | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Connected to Care; Assigned to Arm(s): Connected to Care
C: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Text Messages; Type: EXPERIMENTAL; Interventions: Other: Daily Text Messages | Intervention Type: OTHER; Name: Daily Text Messages; Assigned to Arm(s): Text Messages
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Text messaging reminders | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Text messaging reminders; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Text Message Reminders on Contraceptive Continuation, a Randomized Controlled Trial
Brief Summary: Teen girls and young women taking birth control pills may forget to take their pills or may stop taking them altogether. This places them at risk for unintended pregnancies. Most young women own cell phones and use them for text messaging. We will test whether contraceptive continuation is affected after six months of daily text message reminders.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Text messaging reminders | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Text messaging reminders; Assigned to Arm(s): 1
B: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Text Messages; Type: EXPERIMENTAL; Interventions: Other: Daily Text Messages | Intervention Type: OTHER; Name: Daily Text Messages; Assigned to Arm(s): Text Messages
C: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: follow-up phone counseling | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: follow-up phone counseling; Assigned to Arm(s): Treatment
D: Arm Label: copper intrauterine device; Type: ACTIVE_COMPARATOR; Interventions: Device: copper-releasing intrauterine device, Device: ENG-releasing implant, Device: LNG-releasing intrauterine system, Device: LNG-IUS | Arm Label: LNG-releasing intrauterine system; Type: ACTIVE_COMPARATOR; Interventions: Device: ENG-releasing implant, Device: LNG-releasing intrauterine system, Device: LNG-IUS | Arm Label: ENG-releasing implant; Type: ACTIVE_COMPARATOR; Interventions: Device: ENG-releasing implant, Device: LNG-releasing intrauterine system, Device: LNG-IUS | Intervention Type: DEVICE; Name: copper-releasing intrauterine device; Assigned to Arm(s): copper intrauterine device | Intervention Type: DEVICE; Name: ENG-releasing implant; Assigned to Arm(s): ENG-releasing implant, LNG-releasing intrauterine system, copper intrauterine device | Intervention Type: DEVICE; Name: LNG-releasing intrauterine system; Assigned to Arm(s): ENG-releasing implant, LNG-releasing intrauterine system, copper intrauterine device | Intervention Type: DEVICE; Name: LNG-IUS; Assigned to Arm(s): ENG-releasing implant, LNG-releasing intrauterine system, copper intrauterine device

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Text Message Reminders on Contraceptive Continuation, a Randomized Controlled Trial
Brief Summary: Teen girls and young women taking birth control pills may forget to take their pills or may stop taking them altogether. This places them at risk for unintended pregnancies. Most young women own cell phones and use them for text messaging. We will test whether contraceptive continuation is affected after six months of daily text message reminders.


Options:
A: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Text Messages; Type: EXPERIMENTAL; Interventions: Other: Daily Text Messages | Intervention Type: OTHER; Name: Daily Text Messages; Assigned to Arm(s): Text Messages
B: Arm Label: Mobile phone-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone-based intervention | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mobile phone-based intervention; Assigned to Arm(s): Mobile phone-based intervention
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Text messaging reminders | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Text messaging reminders; Assigned to Arm(s): 1
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Cell Phone Intervention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cell Phone Intervention; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Text Message Reminders on Contraceptive Continuation, a Randomized Controlled Trial
Brief Summary: Teen girls and young women taking birth control pills may forget to take their pills or may stop taking them altogether. This places them at risk for unintended pregnancies. Most young women own cell phones and use them for text messaging. We will test whether contraceptive continuation is affected after six months of daily text message reminders.


Options:
A: Arm Label: 1 Standard Care (SC); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2 Standard Care + Educational (SCE); Type: OTHER; Interventions: Behavioral: educational instruction in clinic | Arm Label: 3 Standard Care + Educational + Phone Calls (SCEP); Type: OTHER; Interventions: Behavioral: educational instruction and phone follow-up | Intervention Type: BEHAVIORAL; Name: educational instruction and phone follow-up; Assigned to Arm(s): 3 Standard Care + Educational + Phone Calls (SCEP) | Intervention Type: BEHAVIORAL; Name: educational instruction in clinic; Assigned to Arm(s): 2 Standard Care + Educational (SCE)
B: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Text Messages; Type: EXPERIMENTAL; Interventions: Other: Daily Text Messages | Intervention Type: OTHER; Name: Daily Text Messages; Assigned to Arm(s): Text Messages
C: Arm Label: Comparison; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: HIV prevention intervention; Type: EXPERIMENTAL; Interventions: Behavioral: HIV prevention intervention | Intervention Type: BEHAVIORAL; Name: HIV prevention intervention; Assigned to Arm(s): HIV prevention intervention
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Structured contraceptive counseling | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Structured contraceptive counseling; Assigned to Arm(s): 1

Answer: B